Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
 
Trade NameVIDAS TPSA ASSAY
Classification Nametotal,prostate specific antigen(noncomplexed&complexed) for detection of prostate cancer
Generic Nametotal prostate specific antigen immunoassay
ApplicantBIOMERIEUX, INC.
PMA NumberP040008
Date Received02/17/2004
Decision Date07/08/2004
Product Code
MTF[ Registered Establishments with MTF ]
Docket Number 04M-0342
Notice Date 08/04/2004
Advisory Committee Immunology
Expedited Review Granted? No
Combination Product No
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Approval Order Statement 
Approval for the vidas tpsa assay indicated as follows: vidas tpsa is intended for use with a vidas (vitek immunodiagnostic assay system) instrument as an automated enzyme-linked fluorescent immunoassay (elfa) for the quantitative measurement of total prostate specific antigen in human serum. The vidas tpsa assay is indicated as an aid in the management of patients with prostate cancer and as an aid in the detection of prostate cancer in conjunction with digital rectal examination (dre) in men age 50 years or older. Prostate biopsy is required for diagnosis of prostate cancer.
Approval Order Approval Order
Supplements: S001 S002 S003 S004 S005 S006 
-
-